

David H Howard

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4533205/publications.pdf>

Version: 2024-02-01

109
papers

3,767
citations

147566

31
h-index

138251

58
g-index

112
all docs

112
docs citations

112
times ranked

5065
citing authors

#	ARTICLE	IF	CITATIONS
1	Producing Organ Donors. <i>Journal of Economic Perspectives</i> , 2007, 21, 25-36.	2.7	478
2	The impact of low health literacy on the medical costs of Medicare managed care enrollees. <i>American Journal of Medicine</i> , 2005, 118, 371-377.	0.6	391
3	Pricing in the Market for Anticancer Drugs. <i>Journal of Economic Perspectives</i> , 2015, 29, 139-162.	2.7	379
4	Impact of health literacy on socioeconomic and racial differences in health in an elderly population. <i>Journal of General Internal Medicine</i> , 2006, 21, 857-861.	1.3	257
5	Association Between Combined <i>TMPRSS2:ERG</i> and <i>PCA3</i> RNA Urinary Testing and Detection of Aggressive Prostate Cancer. <i>JAMA Oncology</i> , 2017, 3, 1085.	3.4	120
6	The Global Impact of Drug Resistance. <i>Clinical Infectious Diseases</i> , 2003, 36, S4-S10.	2.9	90
7	Racial/ethnic disparities in waitlisting for deceased donor kidney transplantation 1 year after implementation of the new national kidney allocation system. <i>American Journal of Transplantation</i> , 2018, 18, 1936-1946.	2.6	84
8	New Kidney Allocation System Associated With Increased Rates Of Transplants Among Black And Hispanic Patients. <i>Health Affairs</i> , 2017, 36, 1078-1085.	2.5	79
9	Absenteeism and Employer Costs Associated With Chronic Diseases and Health Risk Factors in the US Workforce. <i>Preventing Chronic Disease</i> , 2016, 13, E141.	1.7	70
10	Measuring the Economic Costs of Antimicrobial Resistance in Hospital Settings: Summary of the Centers for Disease Control and Prevention’s Emory Workshop. <i>Clinical Infectious Diseases</i> , 2001, 33, 1573-1578.	2.9	66
11	Does Quality Improvement Work? Evaluation of the Organ Donation Breakthrough Collaborative. <i>Health Services Research</i> , 2007, 42, 2160-2173.	1.0	65
12	Comorbidities, smoking status, and life expectancy among individuals eligible for lung cancer screening. <i>Cancer</i> , 2015, 121, 4341-4347.	2.0	59
13	Why do transplant surgeons turn down organs?. <i>Journal of Health Economics</i> , 2002, 21, 957-969.	1.3	57
14	Mandatory Shared Decision Making by the Centers for Medicare & Medicaid Services for Cardiovascular Procedures and Other Tests. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 641.	3.8	56
15	Mammography rates after the 2009 US Preventive Services Task Force breast cancer screening recommendation. <i>Preventive Medicine</i> , 2012, 55, 485-487.	1.6	47
16	Drug Companies' Patient-Assistance Programs – Helping Patients or Profits?. <i>New England Journal of Medicine</i> , 2014, 371, 97-99.	13.9	44
17	Cervical cancer screening of underserved women in the United States: results from the National Breast and Cervical Cancer Early Detection Program, 1997-2012. <i>Cancer Causes and Control</i> , 2015, 26, 671-686.	0.8	43
18	Necitumumab in Metastatic Squamous Cell Lung Cancer. <i>JAMA Oncology</i> , 2015, 1, 1293.	3.4	43

#	ARTICLE	IF	CITATIONS
19	Adoption of Prebiopsy Magnetic Resonance Imaging for Men Undergoing Prostate Biopsy in the United States. <i>Urology</i> , 2018, 117, 57-63.	0.5	43
20	Breast cancer screening of underserved women in the USA: results from the National Breast and Cervical Cancer Early Detection Program, 1998â€“2012. <i>Cancer Causes and Control</i> , 2015, 26, 657-668.	0.8	42
21	The Value of New Chemotherapeutic Agents for Metastatic Colorectal Cancer. <i>Archives of Internal Medicine</i> , 2010, 170, 537.	4.3	41
22	The Economic Burden of Drug Resistance. <i>Clinical Infectious Diseases</i> , 2005, 41, S283-S286.	2.9	40
23	Life expectancy and the value of early detection. <i>Journal of Health Economics</i> , 2005, 24, 891-906.	1.3	40
24	Hospital Readmission Is Associated With Poor Survival After Esophagectomy for Esophageal Cancer. <i>Annals of Thoracic Surgery</i> , 2015, 99, 292-297.	0.7	40
25	National estimates of medical costs incurred by nonelderly cancer patients. <i>Cancer</i> , 2004, 100, 883-891.	2.0	37
26	New Anticancer Drugs Associated With Large Increases In Costs And Life Expectancy. <i>Health Affairs</i> , 2016, 35, 1581-1587.	2.5	37
27	Do Report Cards Influence Hospital Choice? The Case of Kidney Transplantation. <i>Inquiry (United Tj ETQq1 1 0.784314 rgBT /Overlock</i>	0.5	36
28	Use of Cost-Effectiveness Analysis to Determine Inventory Size for a National Cord Blood Bank. <i>Medical Decision Making</i> , 2008, 28, 243-253.	1.2	36
29	Influenza vaccination rates and beliefs about vaccination among nursing home employees. <i>American Journal of Infection Control</i> , 2015, 43, 100-106.	1.1	36
30	Cost Effectiveness Analysis of Pharmacokinetically-Guided 5-Fluorouracil in FOLFOX Chemotherapy for Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2014, 13, 219-225.	1.0	35
31	Prostate Cancer Screening In Men Ages 75 And Older Fell By 8 Percentage Points After Task Force Recommendation. <i>Health Affairs</i> , 2013, 32, 596-602.	2.5	34
32	Quality and Consumer Choice in Healthcare: Evidence from Kidney Transplantation. <i>BE Journal of Economic Analysis and Policy</i> , 2006, 5, 1349.	0.3	31
33	Trends in <sc>PCI</sc> Volume after Negative Results from the <sc>COURAGE</sc> Trial. <i>Health Services Research</i> , 2014, 49, 153-170.	1.0	31
34	Should We Promote Organ Donor Registries When So Few Registrants Will End Up Being Donors?. <i>Medical Decision Making</i> , 2007, 27, 243-249.	1.2	29
35	Abandonment of Highâ€“Dose Chemotherapy/Hematopoietic Cell Transplants for Breast Cancer Following Negative Trial Results. <i>Health Services Research</i> , 2011, 46, 1762-1777.	1.0	28
36	Declines in Prostate Cancer Incidence After Changes in Screening Recommendations. <i>Archives of Internal Medicine</i> , 2012, 172, 1267.	4.3	28

#	ARTICLE	IF	CITATIONS
37	Trends in the Use of Knee Arthroscopy in Adults. <i>JAMA Internal Medicine</i> , 2018, 178, 1557.	2.6	28
38	Resistance-induced antibiotic substitution. <i>Health Economics (United Kingdom)</i> , 2004, 13, 585-595.	0.8	26
39	Cancer Screening And Age In The United States And Europe. <i>Health Affairs</i> , 2009, 28, 1838-1847.	2.5	26
40	The impact of a national program to provide free mammograms to low-income, uninsured women on breast cancer mortality rates. <i>Cancer</i> , 2010, 116, 4456-4462.	2.0	25
41	Hospitalization Rates Among Dialysis Patients During Hurricane Katrina. <i>Prehospital and Disaster Medicine</i> , 2012, 27, 325-329.	0.7	25
42	End-of-Life Medical Costs of Medicaid Cancer Patients. <i>Health Services Research</i> , 2015, 50, 690-709.	1.0	25
43	Trends in the use of active surveillance and treatments in Medicare beneficiaries diagnosed with localized prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 432.e1-432.e10.	0.8	23
44	Adverse Effects of Prohibiting Narrow Provider Networks. <i>New England Journal of Medicine</i> , 2014, 371, 591-593.	13.9	22
45	Evidence Of No Benefit From Knee Surgery For Osteoarthritis Led To Coverage Changes And Is Linked To Decline In Procedures. <i>Health Affairs</i> , 2012, 31, 2242-2249.	2.5	20
46	Changes in Geographic Variation in the Use of Percutaneous Coronary Intervention for Stable Ischemic Heart Disease After Publication of the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) Trial. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2014, 7, 125-130.	0.9	20
47	Psychiatric Practice Patterns and Barriers to the Adoption of Esketamine. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 1039.	3.8	20
48	Association of Mandatory-Access Prescription Drug Monitoring Programs With Opioid Prescriptions Among Medicare Patients Treated by a Medical or Hematologic Oncologist. <i>JAMA Oncology</i> , 2020, 6, 1102.	3.4	20
49	Producing Evidence to Reduce Low-Value Care. <i>JAMA Internal Medicine</i> , 2015, 175, 1893.	2.6	18
50	Impact of Negative Clinical Trial Results for Vertebroplasty on Vertebral Augmentation Procedure Rates. <i>Journal of the American College of Surgeons</i> , 2014, 219, 525-533.e1.	0.2	17
51	Contrary To Conventional Wisdom, Physicians Abandoned A Breast Cancer Treatment After A Trial Concluded It Was Ineffective. <i>Health Affairs</i> , 2016, 35, 1309-1315.	2.5	17
52	Alternative Payment for Radiation Oncology. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 1859.	3.8	17
53	The impact of detection and treatment on lifetime medical costs for patients with precancerous polyps and colorectal cancer. <i>Health Economics (United Kingdom)</i> , 2009, 18, 1381-1393.	0.8	16
54	Mammography rates after the 2009 revision to the United States Preventive Services Task Force breast cancer screening recommendation. <i>Cancer Causes and Control</i> , 2017, 28, 41-48.	0.8	16

#	ARTICLE	IF	CITATIONS
55	Understanding recent increases in chronic disease treatment rates: more disease or more detection?. Health Economics, Policy and Law, 2010, 5, 411-435.	1.1	14
56	The eligibility and reach of the national breast and cervical cancer early detection program after implementation of the affordable care act. Cancer Causes and Control, 2020, 31, 473-489.	0.8	14
57	THE EFFECT OF CADAVERIC KIDNEY DONATIONS ON LIVING KIDNEY DONATIONS: AN INSTRUMENTAL VARIABLES APPROACH. Economic Inquiry, 2013, 51, 1696-1714.	1.0	13
58	Comparative Effectiveness Research, Technological Abandonment, and Health Care Spending. Advances in Health Economics and Health Services Research, 2012, 23, 103-121.	0.2	12
59	Cost-Savings to Medicare From Pre-Medicare Colorectal Cancer Screening. Medical Care, 2015, 53, 630-638.	1.1	12
60	Sociodemographic disparities in treatment and survival of small localized renal cell carcinoma: surgical resection versus thermal ablation. Journal of Comparative Effectiveness Research, 2016, 5, 441-452.	0.6	12
61	Initial and Follow-up Costs by Treatment Outcome for Children With Respiratory Infections. Pediatrics, 2004, 113, 1352-1356.	1.0	11
62	Hospital Quality and Selective Contracting: Evidence from Kidney Transplantation. Forum for Health Economics and Policy, 2008, 11, 2.	0.2	11
63	SUBSIDIZING ALTRUISM IN LIVING ORGAN DONATION. Economic Inquiry, 2018, 56, 398-423.	1.0	11
64	The accuracy of claims data for measuring transfusion rates. Transfusion Medicine, 2016, 26, 457-459.	0.5	10
65	Relationship Between Adherence to Antihypertensive Medication Regimen and Out-of-Pocket Costs Among People Aged 35 to 64 With Employer-Sponsored Health Insurance. Preventing Chronic Disease, 2019, 16, E32.	1.7	10
66	Physician age and the abandonment of episiotomy. Health Services Research, 2019, 54, 650-657.	1.0	10
67	Selective Hearing: Physician Ownership and Physicians'™ Response to New Evidence. Journal of Economics and Management Strategy, 2017, 26, 152-168.	0.4	9
68	Eliminating cost-sharing requirements for colon cancer screening in Medicare. Cancer, 2014, 120, 3850-3852.	2.0	8
69	Sociodemographic impact on survival in unresectable hepatocellular carcinoma: a survival epidemiology and end results study. Future Oncology, 2016, 12, 183-198.	1.1	8
70	Patterns of use and survival outcomes of positron emission tomography for initial staging in elderly follicular lymphoma patients. Leukemia and Lymphoma, 2017, 58, 1570-1580.	0.6	8
71	Intensity-Modulated Radiation Therapy in Breast Cancer Patients Following the Release of a Choosing Wisely Recommendation. Journal of the National Cancer Institute, 2020, 112, 314-317.	3.0	8
72	WAITING TIME AS A PRICE FOR DECEASED DONOR KIDNEYS*. Contemporary Economic Policy, 2011, 29, 295-303.	0.8	7

#	ARTICLE	IF	CITATIONS
73	Serious Health Events and Discontinuation of Routine Cancer Screening. <i>Medical Decision Making</i> , 2012, 32, 627-635.	1.2	7
74	Can major systematic reviews influence practice patterns? A case study of episiotomy trends. <i>Archives of Gynecology and Obstetrics</i> , 2013, 288, 1285-1293.	0.8	7
75	The Living Donor Lost Wages Trial: Study Rationale and Protocol. <i>Current Transplantation Reports</i> , 2018, 5, 45-54.	0.9	7
76	Deterrence effects of antifraud and abuse enforcement in health care. <i>Journal of Health Economics</i> , 2021, 75, 102405.	1.3	7
77	Drivers of <sc>US</sc> health care spending for persons with seizures and/or epilepsies, 2010â€“2018. <i>Epilepsia</i> , 2022, 63, 2144-2154.	2.6	7
78	Variation in Use of Prostate Biopsy Following Changes in Prostate Cancer Screening Guidelines. <i>Journal of Urology</i> , 2017, 198, 1046-1053.	0.2	6
79	Impact of prebiopsy magnetic resonance imaging of the prostate on cancer detection and treatment patterns. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 181.e15-181.e21.	0.8	6
80	US False Claims Act Investigations of Unnecessary Percutaneous Coronary Interventions. <i>JAMA Internal Medicine</i> , 2020, 180, 1534.	2.6	6
81	Disparities in magnetic resonance imaging of the prostate for traditionally underserved patients with prostate cancer. <i>Cancer</i> , 2021, 127, 2974-2979.	2.0	6
82	The value of new drugs for advanced prostate cancer. <i>Cancer</i> , 2021, 127, 3457-3465.	2.0	6
83	The Relationship between Ex Ante Mortality Risk and End-of-Life Medical Costs. <i>Applied Health Economics and Health Policy</i> , 2006, 5, 37-44.	1.0	5
84	False Claims Act Liability for Overtreatment. <i>Journal of Health Politics, Policy and Law</i> , 2020, 45, 419-437.	0.9	5
85	Cancer-directed therapy and potential impact on survivals in nonresected hepatocellular carcinoma: SEER-Medicare population study. <i>Future Oncology</i> , 2017, 13, 2021-2033.	1.1	4
86	Does Bad News Travel Faster? On the Determinants of Medical Technology Abandonment. <i>Journal of Human Capital</i> , 2018, 12, 569-603.	0.6	4
87	Payments and Patient Cost Sharing for Prostate Biopsies According to Image Guidance, Practice Site and Use of Anesthesia. <i>Urology Practice</i> , 2020, 7, 138-144.	0.2	4
88	Nursing homesâ€™ preparedness plans and capabilities. <i>American Journal of Disaster Medicine</i> , 2012, 7, 127-135.	0.1	4
89	Realigning Incentives for Developing and Pricing New Anticancer Treatments. <i>JAMA - Journal of the American Medical Association</i> , 2011, 305, 2347.	3.8	3
90	Trends in transfusion rates after the FOCUS trial. <i>Journal of Comparative Effectiveness Research</i> , 2018, 7, 113-120.	0.6	3

#	ARTICLE	IF	CITATIONS
91	Cancer Survivorship and Supportive Care Economics Research: Current Challenges and Next Steps. Journal of the National Cancer Institute Monographs, 2022, 2022, 57-63.	0.9	3
92	Hospital and skilled nursing facility patient flows during Hurricane Katrina and the Midwest floods of 2008. Health Systems, 2015, 4, 29-40.	0.9	2
93	Capsule Commentary on Mehta et al. Race/Ethnicity and Adoption of a Population Health Management Approach to Colorectal Cancer Screening in a Community-Based Healthcare System. Journal of General Internal Medicine, 2016, 31, 1356-1356.	1.3	2
94	Association Between Self-Reported Hypertension and Antihypertensive Medication Use and Cardiovascular Disease-Related Events and Expenditures Among Patients Diagnosed With Hypertension. Public Health Reports, 2019, 134, 493-501.	1.3	2
95	Medicare fee reductions and the overuse of intensity-modulated radiotherapy. Health Services Research, 2021, 56, 626-634.	1.0	2
96	The Living Donor Lost Wages Trial: Study Rationale and Protocol. Current Transplantation Reports, 2018, 5, 45-54.	0.9	2
97	Physician Reimbursement for Prostate Biopsies Falls as Procedures Shift From Offices to Facilities. Urology, 2018, 115, 96-101.	0.5	1
98	Implementation of Florida Long Term Care Emergency Preparedness Portal Web Site, 2015-2017. American Journal of Public Health, 2018, 108, S399-S401.	1.5	1
99	Cost-effectiveness analysis of regorafenib for metastatic colorectal cancer.. Journal of Clinical Oncology, 2015, 33, 658-658.	0.8	1
100	Provider-owned insurers in the individual market. American Journal of Managed Care, 2018, 24, e393-e398.	0.8	1
101	Rising Medicare Costs: The Authors Respond. Health Affairs, 2006, 25, W391-W392.	2.5	0
102	Just Health: Meeting Health Needs Fairly. JAMA - Journal of the American Medical Association, 2008, 299, 2568.	3.8	0
103	Comparative Effectiveness Research and Cancer Screening in the United States and Europe. Medical Decision Making, 2009, 29, NP12-NP13.	1.2	0
104	Perspectives in Oncology Drug Pricing-Reply. JAMA Oncology, 2016, 2, 402.	3.4	0
105	Radiation Oncology Alternative Payment Model-Reply. JAMA - Journal of the American Medical Association, 2020, 323, 999.	3.8	0
106	Impact of Medicaid reimbursement and eligibility policies on receipt of cancer screening.. Journal of Clinical Oncology, 2013, 31, 6514-6514.	0.8	0
107	Cancer Treatment for Dual Eligibles: What Are the Costs and Who Pays?. American Journal of Cancer Science, 2013, 2, 2013010007.	0.0	0
108	Provider-owned insurers. American Journal of Managed Care, 2017, 23, 566-567.	0.8	0

#	ARTICLE	IF	CITATIONS
109	Inaccurate Comparison of the COVID-19 Response in the United States and Cuba. American Journal of Public Health, 2022, 112, e4-e4.	1.5	0